Clinical Trial Update: Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 BilT-04 trial evaluating gemcitabine and cisplatin with or without CPI-613 (devimistat) for advanced unresectable biliary tract cancer was terminated,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• CPI-613 (devimistat)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Biliary Tract Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-12-31